XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity (Tables)
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Employee Stock-Based Compensation Expense
We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Research and development$9,589 $9,549 $12,841 $18,448 
Selling, general and administrative15,311 15,073 28,720 25,933 
Total stock-based compensation expense$24,900 $24,622 $41,561 $44,381 
Stock-based compensation expense for each type of award under our equity incentive plans and ESPP were as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Stock options$1,877 $3,493 $4,084 $7,171 
Restricted stock units19,757 18,928 32,364 32,001 
Performance stock units1,872 1,581 2,666 3,290 
ESPP1,394 620 2,447 1,919 
Total stock-based compensation expense$24,900 $24,622 $41,561 $44,381 
Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $26.05 per share for the 2023 TSR-based RSUs:
Fair value of Exelixis common stock on grant date
$19.48 
Expected volatility
40.26 %
Risk-free interest rate
3.75 %
Dividend yield
— %